CN101549155A - 猪圆环病毒ⅱ型灭活疫苗及其制备方法 - Google Patents
猪圆环病毒ⅱ型灭活疫苗及其制备方法 Download PDFInfo
- Publication number
- CN101549155A CN101549155A CNA2009100849065A CN200910084906A CN101549155A CN 101549155 A CN101549155 A CN 101549155A CN A2009100849065 A CNA2009100849065 A CN A2009100849065A CN 200910084906 A CN200910084906 A CN 200910084906A CN 101549155 A CN101549155 A CN 101549155A
- Authority
- CN
- China
- Prior art keywords
- circular ring
- inactivated vaccine
- ring virus
- pig circular
- pcv2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940031551 inactivated vaccine Drugs 0.000 title claims abstract description 33
- 241001673669 Porcine circovirus 2 Species 0.000 title abstract description 47
- 238000000034 method Methods 0.000 title abstract description 4
- 241000700605 Viruses Species 0.000 claims abstract description 64
- 239000002671 adjuvant Substances 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 239000000427 antigen Substances 0.000 claims abstract description 10
- 108091007433 antigens Proteins 0.000 claims abstract description 10
- 102000036639 antigens Human genes 0.000 claims abstract description 10
- 231100000614 poison Toxicity 0.000 claims description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 16
- 230000009849 deactivation Effects 0.000 claims description 16
- 238000011218 seed culture Methods 0.000 claims description 14
- 238000011081 inoculation Methods 0.000 claims description 9
- 230000001804 emulsifying effect Effects 0.000 claims description 8
- 229940100198 alkylating agent Drugs 0.000 claims description 7
- 239000002168 alkylating agent Substances 0.000 claims description 7
- 239000002574 poison Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 abstract description 35
- 238000002649 immunization Methods 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 5
- 230000003053 immunization Effects 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 230000002779 inactivation Effects 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000004945 emulsification Methods 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 50
- 238000012360 testing method Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 239000003440 toxic substance Substances 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 230000036039 immunity Effects 0.000 description 9
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 206010058874 Viraemia Diseases 0.000 description 5
- 206010023126 Jaundice Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000000273 veterinary drug Substances 0.000 description 3
- 102100038353 Gremlin-2 Human genes 0.000 description 2
- 101001032860 Mus musculus Gremlin-2 Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000026498 progressive emaciation Diseases 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100849065A CN101549155B (zh) | 2009-05-27 | 2009-05-27 | 猪圆环病毒ⅱ型灭活疫苗及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100849065A CN101549155B (zh) | 2009-05-27 | 2009-05-27 | 猪圆环病毒ⅱ型灭活疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101549155A true CN101549155A (zh) | 2009-10-07 |
CN101549155B CN101549155B (zh) | 2012-05-09 |
Family
ID=41153794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100849065A Active CN101549155B (zh) | 2009-05-27 | 2009-05-27 | 猪圆环病毒ⅱ型灭活疫苗及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101549155B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101934074A (zh) * | 2010-01-28 | 2011-01-05 | 洛阳普莱柯生物工程有限公司 | 猪圆环病毒ⅱ型疫苗及其生产方法 |
CN102154221A (zh) * | 2011-01-05 | 2011-08-17 | 北京大北农科技集团股份有限公司 | 猪圆环病毒ⅱ型毒种的制备和保存方法 |
EP2354221A3 (en) * | 2010-02-04 | 2011-11-23 | Green Cross Veterinary Products Co., Ltd. | Porcine circovirus type 2 and use thereof |
WO2012083837A1 (zh) * | 2010-12-22 | 2012-06-28 | 福又达生物科技股份有限公司 | 猪第二型环状病毒、含彼的免疫组合物、检测套组及其应用 |
CN102787100A (zh) * | 2012-08-30 | 2012-11-21 | 浙江同点生物科技有限公司 | 一种高繁殖能力猪圆环病毒2型毒株及其应用 |
CN103364560A (zh) * | 2013-07-23 | 2013-10-23 | 武汉中博生物股份有限公司 | 一种测定杆状病毒滴度的方法 |
CN104593334A (zh) * | 2015-03-05 | 2015-05-06 | 成都天邦生物制品有限公司 | 低血清培养pk-15细胞生产猪圆环ⅱ型dbn-sx07株病毒的方法 |
CN105087501A (zh) * | 2015-06-11 | 2015-11-25 | 吉林正业生物制品股份有限公司 | 猪圆环病毒2型毒株及由其制备的灭活疫苗和应用 |
CN105920595A (zh) * | 2016-06-23 | 2016-09-07 | 江苏省农业科学院 | 猪圆环病毒2型灭活疫苗及其制备方法 |
-
2009
- 2009-05-27 CN CN2009100849065A patent/CN101549155B/zh active Active
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101934074A (zh) * | 2010-01-28 | 2011-01-05 | 洛阳普莱柯生物工程有限公司 | 猪圆环病毒ⅱ型疫苗及其生产方法 |
CN101934074B (zh) * | 2010-01-28 | 2013-03-06 | 普莱柯生物工程股份有限公司 | 猪圆环病毒ⅱ型疫苗及其生产方法 |
EP2354221A3 (en) * | 2010-02-04 | 2011-11-23 | Green Cross Veterinary Products Co., Ltd. | Porcine circovirus type 2 and use thereof |
CN103314103B (zh) * | 2010-12-22 | 2015-06-24 | 施怀哲维克有限公司 | 猪第二型环状病毒、含彼的免疫组合物、检测套组及其应用 |
WO2012083837A1 (zh) * | 2010-12-22 | 2012-06-28 | 福又达生物科技股份有限公司 | 猪第二型环状病毒、含彼的免疫组合物、检测套组及其应用 |
EA028376B1 (ru) * | 2010-12-22 | 2017-11-30 | Сбк Вирбак Лимитед | Цирковирус свиней 2 типа (цвс2), содержащая его иммуногенная композиция, набор для анализа и их применение |
CN103314103A (zh) * | 2010-12-22 | 2013-09-18 | 施怀哲维克有限公司 | 猪第二型环状病毒、含彼的免疫组合物、检测套组及其应用 |
CN102154221A (zh) * | 2011-01-05 | 2011-08-17 | 北京大北农科技集团股份有限公司 | 猪圆环病毒ⅱ型毒种的制备和保存方法 |
CN102154221B (zh) * | 2011-01-05 | 2013-07-10 | 北京大北农科技集团股份有限公司 | 猪圆环病毒ⅱ型毒种的制备和保存方法 |
CN102787100A (zh) * | 2012-08-30 | 2012-11-21 | 浙江同点生物科技有限公司 | 一种高繁殖能力猪圆环病毒2型毒株及其应用 |
CN102787100B (zh) * | 2012-08-30 | 2013-09-18 | 浙江大学 | 一种高繁殖能力猪圆环病毒2型毒株及其应用 |
CN103364560A (zh) * | 2013-07-23 | 2013-10-23 | 武汉中博生物股份有限公司 | 一种测定杆状病毒滴度的方法 |
CN104593334A (zh) * | 2015-03-05 | 2015-05-06 | 成都天邦生物制品有限公司 | 低血清培养pk-15细胞生产猪圆环ⅱ型dbn-sx07株病毒的方法 |
CN105087501A (zh) * | 2015-06-11 | 2015-11-25 | 吉林正业生物制品股份有限公司 | 猪圆环病毒2型毒株及由其制备的灭活疫苗和应用 |
CN105087501B (zh) * | 2015-06-11 | 2018-09-07 | 吉林正业生物制品股份有限公司 | 猪圆环病毒2型毒株及由其制备的灭活疫苗和应用 |
CN105920595A (zh) * | 2016-06-23 | 2016-09-07 | 江苏省农业科学院 | 猪圆环病毒2型灭活疫苗及其制备方法 |
CN105920595B (zh) * | 2016-06-23 | 2019-09-17 | 江苏省农业科学院 | 猪圆环病毒2型灭活疫苗及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101549155B (zh) | 2012-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101549155B (zh) | 猪圆环病毒ⅱ型灭活疫苗及其制备方法 | |
CN101934074B (zh) | 猪圆环病毒ⅱ型疫苗及其生产方法 | |
CN1056085C (zh) | 母育酚在疫苗中用作佐剂 | |
CN102086447B (zh) | 鸭病毒性肝炎毒株及灭活疫苗 | |
CN109666609A (zh) | 一种赤红球菌发酵方法及其作为佐剂在动物疫苗中的应用 | |
CN103305474A (zh) | 猪伪狂犬病毒毒株及其灭活疫苗和应用 | |
CN104946600B (zh) | 一种h9亚型禽流感病毒株 | |
CN106497890A (zh) | 一种猪伪狂犬病病毒变异株xf‑1株及制备方法和应用 | |
CN103451196A (zh) | 密码子优化的猪圆环病毒2型Cap蛋白编码基因及其应用 | |
CN105688202A (zh) | 一种乙型脑炎疫苗组合物及其制备方法 | |
CN102260649A (zh) | 传染性法氏囊病毒及用鸡胚细胞系和生物反应器繁殖法氏囊病毒制备灭活疫苗和联苗的方法 | |
CN103436499A (zh) | 一种猪圆环病毒样颗粒及其疫苗和制备方法 | |
CN104043117A (zh) | 一种疫苗组合物及其制备方法和应用 | |
CN103908665A (zh) | 一种疫苗组合物及其制备方法和应用 | |
CN108421037A (zh) | 一种猪伪狂犬病/猪细小病毒病二联灭活疫苗及其悬浮培养制备方法 | |
CN107880120A (zh) | 一种猪传染性胃肠炎病毒卵黄抗体及其制备方法 | |
WO2016119078A1 (zh) | 副猪嗜血杆菌lc株与lz-20100109株的联合应用 | |
CN104771754B (zh) | 一种猪圆环病毒2型灭活疫苗水性佐剂及应用 | |
CN104288760A (zh) | 一种疫苗组合物及其制备方法和应用 | |
CN102961742A (zh) | 猪圆环病毒2型与猪细小病毒二联灭活疫苗及其制备方法 | |
CN105521488A (zh) | 猪细小病毒病-猪伪狂犬病二联灭活疫苗及其制备方法和应用 | |
CN106929480A (zh) | 猪繁殖与呼吸综合征病毒株及其应用 | |
CN104474542A (zh) | 一种二联灭活疫苗制备方法 | |
CN103421748B (zh) | 一种猪圆环病毒2型毒株及其应用 | |
TWI682779B (zh) | 豬疾病疫苗用佐劑及其製備方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhao Yarong Inventor after: Wang Guihua Inventor after: Chen Yifeng Inventor after: Xing Haiyun Inventor after: Zhao Jianzeng Inventor before: Xing Haiyun Inventor before: Zhao Jianzeng Inventor before: Zhao Yarong |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: XING HAIYUN ZHAO JIANZENG ZHAO YARONG TO: ZHAO YARONG WANG GUIHUA CHEN YIFENG XING HAIYUN ZHAO JIANZENG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: Garden of Jinan District of Fuzhou City, Fujian province 350014 Village No. 110 Co-patentee after: BEIJING DABEINONG TECHNOLOGY GROUP Co.,Ltd. Patentee after: Zhaofenghua Biotechnology (Fuzhou) Co.,Ltd. Address before: Garden of Jinan District of Fuzhou City, Fujian province 350014 Village No. 110 Co-patentee before: BEIJING DABEINONG TECHNOLOGY GROUP Co.,Ltd. Patentee before: FUZHOU DA BEI NONG BIOTECH Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200903 Address after: 211102, 999 Ting Dong Road, Jiangning economic and Technological Development Zone, Nanjing, Jiangsu Co-patentee after: Zhaofenghua Biotechnology (Fuzhou) Co.,Ltd. Patentee after: Zhaofenghua Biotechnology (Nanjing) Co.,Ltd. Address before: Garden of Jinan District of Fuzhou City, Fujian province 350014 Village No. 110 Co-patentee before: BEIJING DABEINONG TECHNOLOGY GROUP Co.,Ltd. Patentee before: Zhaofenghua Biotechnology (Fuzhou) Co.,Ltd. |
|
TR01 | Transfer of patent right |